Tech Company Financing Transactions
Neurelis Funding Round
Neurelis closed a Series A funding round on 1/7/2017. Backers included HBM Healthcare Investments and private investors.
Transaction Overview
Company Name
Announced On
1/7/2017
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
HBM Healthcare Investments (Lead Investor)
Proceeds Purpose
The company will use the funds to complete clinical trials for NRL-1 (intranasal diazepam), prepare the planned New Drug Application (NDA) for submission to the U.S. Food and Drug Administration (FDA), and begin preparations for the commercial launch of the product.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3430 Carmel Mountain Rd. 300
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Neurelis, Inc. is a specialty pharmaceutical company organized to license, develop, and commercialize product candidates for the treatment of central nervous system disorders with a focus on the treatment of acute breakthrough seizures (epilepsy) and acute anxiety episodes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Craig Chambliss
Chief Financial Officer
George Stuart
Chief Medical Officer
Enrique Carrazana
Chief Scientific Officer
Stuart Madden
Vice President
Chuck DeWildt
Vice President
Adrian Rabinowicz
VP - Bus. Development
Thomas Liquard
VP - General Counsel
Jenny Alonso
VP - Marketing
Steve Jenner
VP - Regulatory Affairs
Edward Smith
Browse more venture capital transactions:
Prev: 1/7/2017: CrediFi venture capital transaction
Next: 1/7/2017: NeoTract venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs